SFI
NBRV

Susquehanna Fundamental Investments’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-692
Closed -$29K – 1853
2021
Q1 		$29K Buy
692
+288
+71% +$17.9K ﹤0.01% 1509
2020
Q4 		$24K Buy
+404
New +$43.8K ﹤0.01% 1467

Other funds holding NBRV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return
VFA
Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Susquehanna Fundamental Investments's NBRV Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2021, closing a stake of 692 shares — an estimated $29K sold.

Susquehanna Fundamental Investments first reported a position in NBRV in Q4 2020 and held it in 2 quarters. The position peaked at $29K in Q1 2021. 31 funds tracked by Wall St. Rank hold NBRV as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 692 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2021, an estimated $29K.
  • Susquehanna Fundamental Investments first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $29K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.